Abatacept in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis

STATUS

Recruiting
participants needed

58
sponsor

University of Leeds

Send

Updated on 19 February 2024

See if I qualify

stiffness

abatacept

arthritis

tenderness

abatacept therapy

Summary

Phase II, single-centre, open label, two parallel arm cohort randomised controlled trial (RCT) testing abatacept in a population of anti-CCP Ab positive individuals at moderate to high risk of developing IA according to a published risk score, already followed in the observational study 'CCP: Next Generation'

Description

There is now evidence that the immunological disease process starts many years before the onset of clinically detectable inflammatory arthritis (IA). It is now a realistic goal to treat individuals in this pre-clinical phase with the possibility of arresting their progression to clinical disease.

Individuals at risk of developing RA can be identified by the presence of CCP antibodies alongside other clinical features. In Leeds we have developed a prediction model that stratifies these individuals into at-risk vs. low risk. At present there are no treatments in this pathway until individuals develop IA.

T-cells appear to be an appropriate target in at-risk individuals as they play a critical role in the generation and maintenance of autoimmunity. Abatacept (Orencia) is a selective Tcell modulator that blocks a co-stimulatory signal needed to activate Tcells and has an excellent safety profile.

Details

Condition	Arthritis
Age	18-100 years
Treatment	Orencia 125 MG Per 1 ML Prefilled Syringe
Clinical Study Identifier	NCT04261023
Sponsor	University of Leeds
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Participant in Leeds CCP 'Next Generation' observational cohort who has tested positive for anti-CCP Ab and accepted to be approached for a interventional study
	Age >18 years old
	At moderate to high risk of progression to IA (see below)
	Consents to be contacted in future for an interventional study
	A prediction model will be used to risk stratify individuals based on the
	following
	predictors
	Tenderness of 1 small joint of the hands or feet defined by the physician (one point)
	Early morning stiffness 30 minutes (one point)
	RF and/or anti-CCP Ab concentration >3x upper limit of normal. (2 points) The participant's risk will be calculated according to the model suggested by Rakieh et al. (1). Those with a score of 3 out of 4 will be eligible to be randomised
	For the intervention arm
	Randomised to intervention arm
	Consents to commence Abatacept therapy (if not, will remain in CCP Next-generation study)
	For the control arm
	Randomised to the control arm
	Will remain in the CCP Next-generation study
Exclusion Criteria
	For both the intervention and control arms
	Previous diagnosis of RA or other form of inflammatory arthritis including, but not limited to SLE, psoriatic arthritis, ankylosing spondylitis, gout or pyrophosphate arthropathy and including current treatment with DMARDs or biological therapy
	Clinical synovitis on clinical examination by a rheumatologist
	Presence of concomitant illness likely to require systemic glucocorticosteroid therapy during the study, in the opinion of the investigator
	Treatment with an intravenous, intramuscular, intrabursal or intraarticular corticosteroid within 12 weeks prior to randomization
	Co-morbidities requiring chronic treatment with immunosuppressive or immune modulating therapy
	Women in the intervention arm who get pregnant during the study will be withdrawn from treatment and followed for the duration of the pregnancy for safety purposes. All participants who get pregnant will continue to be followed up in clinic as standard NHS care to collect secondary end point data
	Evidence of active or latent bacterial or viral infection at the time of potential enrolment, including human immunodeficiency or herpes zoster virus or cytomegalovirus that resolved less than 2 months prior to enrolment
	Individuals with palindromic rheumatism
	For the intervention arm only
	History of acute allergic reactions to biologic therapies or immunoglobulins
	Subjects with current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease, whether or not related to RA and which, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study
	Subjects who have at any time received treatment with any investigational drug within 28 days of the first dose of study drug
	Subjects who test positive for Hepatitis B, C or HIV
	Subjects with tuberculosis (TB), including those at high risk of TB, chronic viral infections, recent serious bacterial infections, subjects receiving live vaccinations within 3 months of the anticipated first dose of study medication, or those with chronic illnesses that would, in the opinion of the investigator, put the participant at risk
	Subjects who currently abuse drugs or alcohol
	Subjects with a history of cancer in the last 5 years, other than non-melanoma skin cell cancers cured by local resection or carcinoma in situ
	Scheduled for or anticipating joint replacement surgery
	Men or women unwilling to use an acceptable method of contraception (detailed in 7.1.4) to avoid pregnancy for up to 14 weeks after the last dose of trial medication
	Women of childbearing potential with a positive serum or urine pregnancy test within 48 hours prior to the baseline visit. Women of child bearing potential are defined as women who have had any menstrual bleeding in the last 24 months and who have not had a hysterectomy or surgical sterilisation
	Evidence of active or latent bacterial or viral infection at the time of potential enrolment, including human immunodeficiency or herpes zoster virus or cytomegalovirus that resolved less than 2 months prior to enrolment
	Inadequate haematological, hepatic or renal function within 28 days of treatment
	Haemoglobin <8.5 g/dL
	White blood cells <3000/mm3
	Platelets <100,000/mm3
	Serum creatinine, ALT or AST >2 times upper limit of normal
	Any other laboratory test result that, in the opinion of the study investigator, might place the participant at unacceptable risk for participation in the study

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Abatacept in Individuals Who aRe Considered At Risk of Developing Inflammatory Arthritis